Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This study is a multi-center, open-label, dose-esclation I/Ib clinical study to explore
safety, efficacy an pharmacokinetics of proxalutamide in patients with metastatic breast
cancer.
This study includes two stages, stage I: single- and multiple-dose tolerance and
pharmacokinetic study; stage 2: preliminary efficacy and safety study.
Phase:
Phase 1
Details
Lead Sponsor:
Suzhou Kintor Pharmaceutical Inc,
Collaborators:
Beijing Cancer Hospital Hebei Medical University Fourth Hospital Hunan Cancer Hospital Ruijin Hospital Sun Yat-sen University The First Affiliated Hospital with Nanjing Medical University Tianjin Medical University Cancer Institute and Hospital